Literature DB >> 25327530

Adverse effects of androgen-deprivation therapy in prostate cancer and their management.

Handoo Rhee1, Jennifer H Gunter, Peter Heathcote, Ken Ho, Phillip Stricker, Niall M Corcoran, Colleen C Nelson.   

Abstract

OBJECTIVE: To provide an up-to-date summary of current literature on the management of adverse effects of androgen-deprivation therapy (ADT). PATIENTS AND METHODS: All relevant medical literature on men with prostate cancer treated with ADT from 2005 to 2014, and older relevant papers, were reviewed. Recent health advisory statements from the Australian government, societies and advocacy groups have been incorporated to the document.
RESULTS: There are numerous adverse effects of ADT that require pro-active prevention and treatment. Ranging from cardiovascular disease, diabetes and osteoporosis, to depression, cognitive decline and sexual dysfunction, the range of adverse effects is wide. Baseline assessment, monitoring, prevention and consultation from a multidisciplinary team are important in minimising the harm from ADT.
CONCLUSIONS: This review provides a series of practical recommendations to assist with managing the adverse effects of ADT.
© 2014 The Authors. BJU International © 2014 BJU International.

Entities:  

Keywords:  adverse effect; androgen-deprivation therapy; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 25327530     DOI: 10.1111/bju.12964

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  43 in total

1.  Prostate cancer reduces endurance exercise capacity in association with reductions in cardiac and skeletal muscle mass in the rat.

Authors:  Peter J Esau; Elizabeth M Gittemeier; Alexander B Opoku-Acheampong; Korynne S Rollins; Dryden R Baumfalk; David C Poole; Timothy I Musch; Bradley J Behnke; Steven W Copp
Journal:  Am J Cancer Res       Date:  2017-12-01       Impact factor: 6.166

2.  Prognostic factors in Chinese patients with prostate cancer receiving primary androgen deprivation therapy: validation of Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score and impacts of pre-existing obesity and diabetes mellitus.

Authors:  Meng-Bo Hu; Tian Yang; Ji-Meng Hu; Wen-Hui Zhu; Hao-Wen Jiang; Qiang Ding
Journal:  Int J Clin Oncol       Date:  2018-01-06       Impact factor: 3.402

Review 3.  Systemic Treatment of Prostate Cancer in Elderly Patients: Current Role and Safety Considerations of Androgen-Targeting Strategies.

Authors:  Myrto Boukovala; Nicholas Spetsieris; Eleni Efstathiou
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

Review 4.  Prevalence of osteoporosis in prostate cancer survivors II: a meta-analysis of men not on androgen deprivation therapy.

Authors:  Annie-Claude M Lassemillante; Suhail A R Doi; John D Hooper; John B Prins; Olivia R L Wright
Journal:  Endocrine       Date:  2015-01-31       Impact factor: 3.633

5.  Castration impairs erectile organ structure and function by inhibiting autophagy and promoting apoptosis of corpus cavernosum smooth muscle cells in rats.

Authors:  Xian-Jin Wang; Tian-Yuan Xu; Lei-Lei Xia; Shan Zhong; Xiao-Hua Zhang; Zhao-Wei Zhu; Dong-Rui Chen; Yue Liu; Yong Fan; Chen Xu; Min-Guang Zhang; Zhou-Jun Shen
Journal:  Int Urol Nephrol       Date:  2015-05-22       Impact factor: 2.370

6.  Effects of resistance training frequency on physical functioning and quality of life in prostate cancer survivors: a pilot randomized controlled trial.

Authors:  M K Norris; G J Bell; S North; K S Courneya
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-06-16       Impact factor: 5.554

Review 7.  Cardiovascular Complications of Androgen Deprivation Therapy for Prostate Cancer.

Authors:  Dipti Gupta; Chadi Salmane; Susan Slovin; Richard M Steingart
Journal:  Curr Treat Options Cardiovasc Med       Date:  2017-08

8.  Interventions to address sexual problems in people with cancer.

Authors:  L Barbera; C Zwaal; D Elterman; K McPherson; W Wolfman; A Katz; A Matthew
Journal:  Curr Oncol       Date:  2017-06-27       Impact factor: 3.677

9.  Risk of renal stone formation in patients treated with luteinising hormone-releasing hormone analogues for prostate cancer: importance of bone metabolism and urine calcium.

Authors:  Enrique Diaz-Convalia; Miguel Angel Arrabal-Polo; Maria Del Carmen Cano-Garcia; Alejandro Dominguez-Amillo; Nelson Canales-Casco; Miguel Arrabal-Martin
Journal:  Int Urol Nephrol       Date:  2018-01-27       Impact factor: 2.370

Review 10.  Metabolic Syndrome and Prostate Cancer: a Review of Complex Interplay Amongst Various Endocrine Factors in the Pathophysiology and Progression of Prostate Cancer.

Authors:  Handoo Rhee; Ian Vela; Eric Chung
Journal:  Horm Cancer       Date:  2015-11-06       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.